Immunomodulator

OK, I know what you are thinking. Am I not the same guy who has been spouting off about our new dry eye world of “and,” not “either/or?” It is only a little more than a year in this new treatment paradigm, and I am already changing my tune?

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study published in The New England Journal of Medicine.

A phase 2 clinical trial of VVN461, a nonsteroidal dual Janus kinase 1/tyrosine kinase 2 immunomodulator, met the primary endpoint of statistical and clinical efficacy vs. vehicle for the treatment of inflammation after cataract surgery.

It is September once again, time for us to review the state of the anti-inflammatory landscape in the world of dry eye disease.

Half of patients with long COVID demonstrate persistent inflammation and may potentially benefit from immunomodulation, according to data.

Cumulative exposure to immunomodulators increased the risk for high-grade cervical intraepithelial neoplasia and cervical cancer in women with inflammatory bowel disease, according to data from Alimentary Pharmacology & Therapeutics.

WASHINGTON — Pegylated interferon alpha potentiated the antiviral activity of VIR-2218 in a small subset of noncirrhotic patients with chronic hepatitis B, according to preliminary data presented at The Liver Meeting.

Man, this sure is not turning into one of those “nothing to see here” columns.

Mesalamine correlated with the longest life expectancy among older adult patients with inflammatory bowel disease, according to research published in BMC Gastroenterology.